MorphoSys AG (MPSYF)
MorphoSys AG operates in the Biotechnology industry of the Healthcare sector, headquartered in Planegg, DE. The stock last traded at $73.27, up 2.10% on the session, giving a market capitalisation of $2.76B. On trailing twelve-month figures it carries a trailing P/E of -11.62, a net margin of -79.6%. Its beta of 0.66 implies it has historically moved less than the broad market.
MorphoSys AG is a biopharmaceutical firm with therapies already on the market, specializing in the discovery, advancement, and commercialization of antibody-based treatments for individuals battling cancer and autoimmune diseases. Among its key offerings is Tafasitamab, an antibody therapy approved for treating specific B-cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also boasts a robust pipeline, with several promising candidates under development. These include Pelabresib, a small molecule currently in Phase II clinical trials for myelofibrosis, and Felzartamab, a CD38-targeting antibody undergoing Phase I/II investigation for anti-PLA2R-positive membranous nephropathy, an autoimmune kidney disorder. Additionally, MorphoSys is developing CPI-0209, a small molecule in Phase I/II designed to promote anti-tumor activity by inhibiting EZH2. Beyond its proprietary projects, MorphoSys collaborates with pharmaceutical partners on other therapeutic programs. These include Gantenerumab for Alzheimer's disease, Otilimab for rheumatoid arthritis, Tremfya for psoriasis, psoriatic arthritis, and palmoplantar pustulosis, and MOR210/TJ210 targeting immuno-oncology and autoimmune conditions. The company has forged several strategic alliances to further its mission. Notable partnerships include a regional licensing agreement with I-Mab Biopharma for the development and commercialization of felzartamab across China, Taiwan, Hong Kong, and Macau, as well as a strategic alliance with LEO Pharma. Furthermore, MorphoSys has a joint collaboration and licensing pact with Incyte Corporation for the development and market introduction of tafasitamab. It also participates in a clinical collaboration with Incyte Corporation and Xencor, Inc. to evaluate a combination therapy of tafasitamab, plamotamab, and lenalidomide for patients with relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma. Established in 1992, MorphoSys AG maintains its headquarters in Planegg, Germany.
MorphoSys AG is most often compared with the following Healthcare names: